Article Sidebar

Submitted
Sep 9, 2023
Published
Sep 9, 2023
Download
PDF
Statistic
Read Counter : 69 Download : 60

Main Article Content

Abstract

Cardiovascular diseases (CVD’s) are the group of diseases of the heart and blood vessels the most common cause of the CVD’s are atherosclerosis , (plaque build-up in the arteries)some of the CVD’s are MI , IHD, coronary artery disease, valve disease, heart failure, aneurism.The Review focused on the effective use of antibiotics in CVD’s in that we study about CVD’s like CHD, MI and IHD so we find that the Chlamydiapneumonia may increases the risk of developing cardiovascular diseases . some studies shows that the Chlamydiapneumonia species may found in damaged vascular tissue and arteries of the heart and some of the bacteria like Helicobacter pylori , Cytomegalovirus , may also develop atherosclerotic lesions in that some of clinical trails shows that the macrolide antibiotics like Azithromycin, roxithromycin, oxithromycin antibiotics may shows a greater efficacy against Chlamydiapneumonia and they reduces the plaque stabilization but there is no proper therapy for killing of Chlamydiapneumonia in patients with CVD. But killing of an inflammatory condition in patients with CVD may reduces the risk of CVD’s so several clinical trails are require to perform the proper and effective use of antibiotics in CVD’s  in this we study we tell about that there is an use of macrolide antibiotics may reduces or may cure the risk of developing the cardiovascular diseases .

Keywords

Antibiotics Cardiovascular diseases Helicobacter pylori Chlamydiapneumonia

Article Details

How to Cite
Valaparla. Geetha rani, Shaik. Umar faruk, Kommathoti. Akhila Chilaka, & Dileep kumar. (2023). Importance of antibiotics in cardiovascular diseases. International Journal of Research in Pharmacology & Pharmacotherapeutics, 12(3), 205-209. https://doi.org/10.61096/ijrpp.v12.iss3.2023.205-209
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. American Heart Association. 2000 heart and stroke statistical update. Dallas: AHA Press; 1999.
  2. 2. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseasemortality in Europe. Task force of the European Society of Cardiology on cardiovascular mortality and morbidity statistics in Europe. Eur Heart J. 1997;18(8):1231-48. doi: 10.1093/oxfordjournals.eurheartj.a015434.
  3. 3. Dai X, Wiernek S, Evans JP, Runge MS. Genetics of coronary artery disease and myocardial infarction. World J Cardiol. 2016;8(1):1-23. doi: 10.4330/wjc.v8.i1.1, PMID 26839654.
  4. 4. Libby P. The pathogenesis of atherosclerosis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. 15th ed. Harrison’sprinciples of internal medicine. New York: McGraw-Hill; 2001. p. 1377-82.
  5. 5. Muhlestein JB. Chronic infection and coronary artery disease. Med Clin North Am. 2000;84(1):123-48. doi: 10.1016/s0025-7125(05)70210-8, PMID 10685131.
  6. 6. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation. 1998;97(17):1675-9. doi: 10.1161/01.cir.97.17.1675, PMID 9591760.
  7. 7. Cook PJ, Lip GYH. Infectious agents and atherosclerotic vasculardisease. Q J Med. 1996;89(10):727-36. doi: 10.1093/qjmed/89.10.727.
  8. 8. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation. 1998;97(17):1675-9. doi: 10.1161/01.cir.97.17.1675, PMID 9591760.
  9. 9. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascularevents and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96(2):404-7. doi: 10.1161/01.cir.96.2.404, PMID 9244203.
  10. 10. Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, et al. Chlamydia pneumoniae strain TWAR antibody and angiographicallydemonstrated coronary artery disease. Arterioscler Thromb. 1991;11(3):547-51. doi: 10.1161/01.atv.11.3.547, PMID 2029495.
  11. 11. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittacistrain,TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986;315(3):161-8. doi: 10.1056/NEJM198607173150305, PMID 3724806.
  12. 12. Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis. 1985;151(5):832-9. doi: 10.1093/infdis/151.5.832, PMID 3886806.
  13. 13. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, et al. Serologic evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease andacute myocardial infarction. Lancet. 1988;2(8618):983-6. doi: 10.1016/s0140-6736(88)90741-6, PMID 2902492.
  14. 14. Aldous MB, Grayston JT, Wang SP, Foy HM. Seroepidemiology of Chlamydia pneumoniaeTWAR infection in Seattle families, 1966-79. J Infect Dis. 1992;166(3):646-9. doi: 10.1093/infdis/166.3.646, PMID 1500751.
  15. 15. Beale AS, Masson ND. Susceptibility of Chlamydia pneumoniae to oral agents commonly used in the treatment of respiratory infection. J Antimicrob Chemother. 1994;34(6):1072-4. doi: 10.1093/jac/34.6.1072, PMID 7730224.
  16. 16. Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. Antimicrob Agents Chemother. 1998;42(10):2762-4. doi: 10.1128/AAC.42.10.2762, PMID 9756794.
  17. 17. Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992;14(1):178-82. doi: 10.1093/clinids/14.1.178, PMID 1571425.
  18. 18. Hammerschlag MR. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother. 1994;38(9):1873-8. doi: 10.1128/AAC.38.9.1873, PMID 7810992.
  19. 19. Kuo CC, Jackson LA, Lee A, Grayston JT. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1996;40(11):2669-70. doi: 10.1128/AAC.40.11.2669, PMID 8913488.
  20. 20. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin,clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992;36(7):1573-4. doi: 10.1128/AAC.36.7.1573, PMID 1324650.
  21. 21. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascularevents, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96(2):404-7. doi: 10.1161/01.cir.96.2.404, PMID 9244203.
  22. 22. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of Roxithromycin in non-Q-wave coronary syndromes: ROXISpilot study: ROXIS Study Group. Lancet. 1997;350(9075):404-7. doi: 10.1016/s0140-6736(97)07201-2, PMID 9259655.
  23. 23. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosisand restenosis: an assessment of the evidence and need forfuture research. Circulation. 1997;96(11):4095-103. doi: 10.1161/01.cir.96.11.4095, PMID 9403635.
  24. 24. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of Roxithromycin in non–Q-wave coronary syndromes: ROXIS pilot study. ROXIS Study Group. Lancet. 1997;350(9075):404-7. doi: 10.1016/s0140-6736(97)07201-2, PMID 9259655.
  25. 25. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96(2):404-7. doi: 10.1161/01.cir.96.2.404, PMID 9244203.
  26. 26. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B. Mautner B for the ROXIS study group. Treatment with the antibiotic Roxithromycin in patients with acute non–Q-wave coronary syndromes. Eur Heart J. 1999;20:121-7.
  27. 27. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 1999;99(12):1540-7. doi: 10.1161/01.cir.99.12.1540, PMID 10096928.
  28. 28. Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation. 1996;20(6):693-705. doi: 10.1007/BF01488805, PMID 8979156.
  29. 29. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone. 1998;22(1):33-8. doi: 10.1016/s8756-3282(97)00221-4, PMID 9437511.
  30. 30. Smith GN, Yu LP, Brandt KD, Capello WN. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of humanosteoarthritic cartilage. J Rheumatol. 1998;25(3):532-5. PMID 9517776.
  31. 31. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1199591. 1995;91(11):2844-50. doi: 10.1161/01.cir.91.11.2844, PMID 7758192.
  32. 32. Martin D, Bursill J, Qui MR, Breit SN, Campbell T. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet. 1998;351(9119):1858-9. doi: 10.1016/S0140-6736(05)78804-8, PMID 9652673.
  33. 33. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate theactivity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996;98(11):2572-9. doi: 10.1172/JCI119076, PMID 8958220.
  34. 34. Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation. 1998;97(17):1671-4. doi: 10.1161/01.cir.97.17.1671, PMID 9591759.
  35. 35. Grayston JT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation. 1998;97(17):1669-70. doi: 10.1161/01.cir.97.17.1669, PMID 9591758.
  36. 36. Mitsuyama T, Hidaka K, Furuno T, Hara N. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolidethrough the action of nitric oxide. Int Arch Allergy Immunol. 1997;114(2):111-5. doi: 10.1159/000237654, PMID 9338603.
  37. 37. Chen B, Jiang L, Zhao W, Yu R, Hou XM. Ameliorating effect of erythromycin on bleomycin-induced pulmonary fibrosis: role ofalveolar macrophage activation and cytokine release. Respirology. 1997;2(2):151-5. doi: 10.1111/j.1440-1843.1997.tb00071.x, PMID 9441129.
  38. 38. Miyazawa T, Iino Y. Cell surface antigens on inflammatory cells in the paranasal mucosa of patients after macrolide therapy [in Japanese]. Nippon Jibiinkoka Gakkai Kaiho. 1997;100(6):671-7. doi: 10.3950/jibiinkoka.100.671, PMID 9248279.
  39. 39. Furuno T, Mitsuyama T, Hidaka K, Tanaka T, Hara N. The role of neutrophil elastase in human pulmonary artery endothelial cell injury. Int Arch Allergy Immunol. 1997;112(3):262-9. doi: 10.1159/000237464, PMID 9066513.